Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are not the first to suffer embargo related nightmares
.... anyone remember how the IMMU nightmare ended ...
I do $21bn buy out PRE REVENUE
Presentation Withdrawn on Embargo Complaint
Immunomedics -15%;
By Cristin Flanagan
(Bloomberg) -- Immunomedics says presentation was cancelled because of a third-party complaint that it had violated the embargo by reporting results presented by its Chairman at an April conference.
CEO says IMMU trying to reverse decision, sees April results reported as different from those in the ASCO abstract submitted last Feb.
“Both we and our many investigators involved are disappointed that our excellent therapeutic results, achieving an interim median survival of about 14 months, may not be presented at this meeting. These results are very encouraging for TNBC patients with metastatic disease who failed multiple prior therapies.”
NOTE: Yday, Immunomedics Falls After ASCO Pulls Presentation on Cancer Drug
IMMU down 15% in pre-mkt on 1.4m vol.
Oh yes indeed..
Its Giordano
So you allocated. 6% of your portfolio to NWBO ....
You have several biotech stocks but don't understand FTD are cumulative and literally no different for NWBO than any other stock ...
Now if I was a betting man .....
Byyyeeeeeeee......
what on earth are you talking about ?
Currently a 'long only' institutional investor could reasonably command an allocation price of $1.20- $1.50 for 100m shares .
With data in hand and clinicians, KOL's and a truck load of seemingly regulatory
buy in , if our management cant get that done I assure you it would be 100% down to their lack of credibility .
A real money investor would spend several million dollars on their analysis and DD of the company and its data before putting up a single penny .
They would analyse every press release every word of every ASM , every promise made every time lines hit or missed, they would not leave a single stone unturned.
They would have third party expert consultants and i mean the best of the best pour over every line of the data and even have third parties re-assess all of their own findings and then make a decision based on all all of this.
The may then ask for conditions , like maybe the management return hundreds of millions of their options to the book, or maybe. increase the strike of the options.
They may insist on a restructuring of the board a revers split and a re-listing.
My own SWOT on my 9 1/2 year journey with North West has taken many turns but funnily enough right now the weakness that is Les's utter untrustworthiness and Linda Powers' ' absentee landlord ' status and their joint culture of blaming anyone and everyone but themselves for us being at an intrinsic $800m or less m/c strangely could present to an institutional investor as one less hurdle in a buy out situation because their exit would most certainly be part of any deal.
Flip , Woj ,
Very recently LG said it would be a `household name journal` ..that's certainly not AoO....but anyway I`m the first to admit Les spurts verbal diarrhoea at a rate that I`ve rarely encountered ..... so who knows ...
Merck Phase 3 Keytruda Study Misses Main Endpoint in HNSCC >MRK
By Colin Kellaher
(Dow Jones) -- Merck & Co. on Wednesday said a Phase 3 study of its blockbuster cancer drug Keytruda missed its primary endpoint in patients with unresected locally advanced head and neck squamous cell carcinoma, or HNSCC.
The Kenilworth, N.J., drugmaker said patients receiving Keytruda with concurrent chemoradiation therapy followed by Keytruda as maintenance therapy showed improvement in event-free survival, but the results didn't meet statistical significance.
Merck said the study results show that locally advanced HNSCC remains very challenging to treat, adding that it is committed to investigating Keytruda-based regimens in earlier stages of the disease.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world, including some HNSCC indications.
Sales of Keytruda topped $17 billion last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
Merck Phase 3 Keytruda Study Misses Main Endpoint in HNSCC >MRK
By Colin Kellaher
(Dow Jones) -- Merck & Co. on Wednesday said a Phase 3 study of its blockbuster cancer drug Keytruda missed its primary endpoint in patients with unresected locally advanced head and neck squamous cell carcinoma, or HNSCC.
The Kenilworth, N.J., drugmaker said patients receiving Keytruda with concurrent chemoradiation therapy followed by Keytruda as maintenance therapy showed improvement in event-free survival, but the results didn't meet statistical significance.
Merck said the study results show that locally advanced HNSCC remains very challenging to treat, adding that it is committed to investigating Keytruda-based regimens in earlier stages of the disease.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world, including some HNSCC indications.
Sales of Keytruda topped $17 billion last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
KIPK is said MARKET CAPS caps not price , PPS is irrelevant
when there`s dilution to take into account
Yes they are the PR companyy NWBIO used for JTM and are currently being used for Journal & 'Met End Points` PR
53m shares of which probably 40m was one buyer
Kab ,one buyer and probably a 20% increment from the FOMO brigade took us from mid 80cents to > $2.0 in a handful of sessions.
I know little about the science but this side of the equation I know like the back of my hand , one Tute , just one thats all we need and we will get many many more real money buyers than that .
Powerscourt are a tip top PR firm , the global media attention will be astounding .
ONE PR + ONE JOURNAL =
a) 10 Family offices buying
b) 20 Hedge funds buying
c) and a couple of institutional buyers ( that means Long Only's)
1 buyer got us to $2.08 on the run up to NYAS ...
1 smallish institutional buyer could rally us to $5-$7 easily ...
a+b+c = $14 Bn m/c in the first 5 trading sessions.
I`m baffled ..
1.Which part of my post suggests bombarding them with inquiries and requests .. ?
2. This is a shareholder forum , your message could could apply to literally all of the 400k posts to date ( apart from yours I guess...)
3. Don`t bother answering ... you`re on ignore
...whats the terrible idea I supposedly had ?
What on earth are you talking about ?
Yes exactly that`s why I said $3ish ...
Ex is doing his Google search bit again , which you`ll find is the basis of most of his supposed knowledge
There are companies on OTCQB with markets caps that were in the high single digit billions recently , until the correction we are going through hit anyway ... so why not ...
Depends if its a reverse split then its instantaneous .
UPLIST .
To uplist from the OTCQB to Nasdaq is a seemless event .
Currently the only criteria we don't meet is the PPS .
When we meet that , all we will see is a PR before the market opens and
we will be trading back on Nasdaq within an hour of the PR .
Good email PGSD , thanks
Aek , did you mean to direct that request to me ?... as I haven't got a clue what your talking about
I didn`t see it ...I know it ,
Sajid Javid is talking about DCVAX .
AS FAR AS THE GLOBAL INVESTMENT COMMINUTY ARE CONCERNED
& AS FAR AS THE WORLDS MEDIA ARE CONCERENED
& AS FAR AS THE GENERAL PUBLIC ARE CONCERENED
THE DATA HAS NOT BEEN RELEASED YET ...
THAT ONLY CHANGES WHEN THE `MET ENDPONTS` PR IS RELEASED
AND THEY ARE REFERRED TO A JOURNAL PUBLICATION FOR ADDED VARIFICATION.
OUR SHARE PRICE WILL DRIFT UNTIL THAT DAY ..
THEN AND ONLY THEN DOES EVERYTHIGN CHANGE
Exactly right , try Google / News .`DCVAX met endponts` NOTHING appears and it will remain that way till PR and Journal ....
Thanks ATLnsider...and institutional investors know that perfectly well , but they either cant or wont buy because of either :
a) the exchange we are quoted on is outside their investment mandate or
b) they need the ` met endpoints ` PR which is legally binding.
One real money investor changes everything for us but we should expect 10+++ all looking to take advantage of our ridiculous share price dislocation .
drift till PR and Journal
Prof Ashkan`s & Marnix presentations will be watched by the whole Merck C suite ...today ... guaranteed .
When Keyoumars reached out to Novocure it reinforced his total class and
unwavering desire to just do the best for patients .
I have sent two patients to Keyourmars , they were just full of praise for him
''There are three stages in scientific discovery. First, people deny that it is true, then they deny that it is important; finally they credit the wrong person.“
Bill Bryson
Prof Ashkan`s & Marnix presentations will be watched by the whole Merck C suite ...today ... guaranteed .
When Keyoumars reached out to Novocure it reinforced his total class and
unwavering desire to just do the best for patients .
I have sent two patients to Keyourmars , they were just full of praise for him
Probably one person bought the vast majority and that’s the person who dumped them.
JM100 , highly unlikely , it was as I said one big buyer who had accumulated over the prior few sessions who then hit the sell button when there was no PR … any professional trader would do exactly the same .
I reckon he got in and out. probably close to flat .
Flipper. ...About 53m shares were bought between 90cents at 2.00
on the run in to 10th may .. I watched every trade .. it was in my opinion one
significant buyer .
That buyer dumped the second it was apparent there was no PR , add that to the stops that got hit and there's your 78 m volume on 10th .. as I would do if id bought for a specific event.
We are back to where we started pre the run up .
Our management team have data in hand , imminent peer review publication and end points PR to come and a hugely discounted share price .... if they cant entice some level of institutional interest its simply because they have through years of spewing utter crap , albeit normally Les and latterly Innes , lost all credibility .
Merck is our likely option for and end to this utter misery .
...what an incredible coincidence ..
I`m a a good friend of his brother Nick Hoare - you need Tim died a couple of years back ?
I totally agree - doesn't even need a lawyer in the room with her ..
Sure no problem ...
is he a friend of Bills ?